Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Evaluation</td><td class="align_center"><i>n</i> (%)</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">CR</td><td class="align_center">0 (0)</td></tr><tr><td class="align_left">PR</td><td class="align_center">4 (12.12)</td></tr><tr><td class="align_left">SD</td><td class="align_center">12 (36.36)</td></tr><tr><td class="align_left">PD</td><td class="align_center">17 (51.52)</td></tr><tr><td class="align_left">DCR</td><td class="align_center">16 (48.48)</td></tr><tr><td class="align_left">ORR</td><td class="align_center">4 (12.12)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><div>CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DCR, disease control rate; ORR, objective response rate.<br/></div></td></tr></table>

<div>The efficacy was evaluated at the first follow-up (RECIST1.1).</div>

Journal of Oncology

tab2

Table 2

Table 2: Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer 